Syndax Pharmaceuticals, Inc. $SNDX is Aisling Capital Management LP’s 3rd Largest Position

Aisling Capital Management LP lifted its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 28.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,316,806 shares of the company’s stock after purchasing an additional 291,806 shares during the quarter. Syndax Pharmaceuticals comprises about 3.4% of Aisling Capital Management LP’s portfolio, making the stock its 3rd biggest position. Aisling Capital Management LP owned approximately 1.53% of Syndax Pharmaceuticals worth $12,325,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Quarry LP acquired a new position in shares of Syndax Pharmaceuticals during the first quarter valued at about $25,000. Teacher Retirement System of Texas grew its position in Syndax Pharmaceuticals by 11.9% during the 2nd quarter. Teacher Retirement System of Texas now owns 23,132 shares of the company’s stock worth $217,000 after purchasing an additional 2,458 shares during the last quarter. DAFNA Capital Management LLC increased its stake in Syndax Pharmaceuticals by 0.5% during the 1st quarter. DAFNA Capital Management LLC now owns 544,502 shares of the company’s stock valued at $6,689,000 after purchasing an additional 2,500 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Syndax Pharmaceuticals by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,842 shares of the company’s stock worth $705,000 after buying an additional 3,094 shares during the last quarter. Finally, E Fund Management Co. Ltd. lifted its stake in shares of Syndax Pharmaceuticals by 27.2% during the first quarter. E Fund Management Co. Ltd. now owns 16,031 shares of the company’s stock worth $197,000 after buying an additional 3,428 shares during the period.

Insiders Place Their Bets

In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 157,307 shares of the firm’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $16.41, for a total value of $2,581,407.87. Following the transaction, the chief executive officer owned 298,661 shares in the company, valued at approximately $4,901,027.01. This trade represents a 34.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 4.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. B. Riley raised Syndax Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, August 6th. Barclays boosted their target price on shares of Syndax Pharmaceuticals from $22.00 to $35.00 and gave the company an “overweight” rating in a research report on Monday, November 24th. Wall Street Zen upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Stifel Nicolaus started coverage on shares of Syndax Pharmaceuticals in a research report on Wednesday, September 10th. They set a “buy” rating and a $44.00 price target on the stock. Finally, Citigroup lifted their price objective on shares of Syndax Pharmaceuticals from $46.00 to $51.00 and gave the company a “buy” rating in a report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $37.20.

Syndax Pharmaceuticals Price Performance

Syndax Pharmaceuticals stock opened at $20.12 on Friday. The stock has a market capitalization of $1.75 billion, a P/E ratio of -5.17 and a beta of 0.73. The company’s fifty day moving average price is $15.85 and its 200 day moving average price is $13.24. The company has a debt-to-equity ratio of 2.06, a quick ratio of 4.55 and a current ratio of 4.71. Syndax Pharmaceuticals, Inc. has a 1 year low of $8.58 and a 1 year high of $20.20.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.04. The business had revenue of $45.87 million for the quarter, compared to the consensus estimate of $49.08 million. Syndax Pharmaceuticals had a negative net margin of 428.48% and a negative return on equity of 130.47%. The company’s revenue was up 266.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.98) earnings per share. As a group, equities research analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).